Home » Stocks » GlycoMimetics

GlycoMimetics, Inc. (GLYC)

Stock Price: $3.93 USD -0.07 (-1.75%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $3.95 +0.02 (0.51%) Aug 4, 4:12 PM

Stock Price Chart

Key Info

Market Cap 171.28M
Revenue (ttm) 9.00M
Net Income (ttm) -49.72M
Shares Out 43.58M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $3.93
Previous Close $4.00
Change ($) -0.07
Change (%) -1.75%
Day's Open 4.00
Day's Range 3.88 - 4.09
Day's Volume 439,241
52-Week Range 1.82 - 9.53

More Stats

Market Cap 171.28M
Enterprise Value 24.62M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 43.58M
Float 23.89M
EPS (basic) -1.15
EPS (diluted) -1.14
FCF / Share -1.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.79M
Short Ratio 2.79
Short % of Float 11.63%
Beta 2.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.03
PB Ratio 1.22
Revenue 9.00M
Operating Income -51.65M
Net Income -49.72M
Free Cash Flow -44.34M
Net Cash 146.66M
Net Cash / Share 3.37
Gross Margin n/a
Operating Margin -573.93%
Profit Margin -552.40%
FCF Margin -492.65%
ROA -18.41%
ROE -30.66%
ROIC -2,754.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.25*
(135.37% upside)
Low
4.00
Current: $3.93
High
15.00
Target: 9.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---0.0220.0715.033.9915.263.81
Revenue Growth----99.91%33.56%276.37%-73.83%300.04%-
Gross Profit---0.0220.0715.033.9915.263.81
Operating Income-61.39-51.50-33.93-31.91-12.78-11.14-10.613.64-6.08
Net Income-57.89-48.27-33.28-31.81-12.77-11.12-10.613.66-6.11
Shares Outstanding43.2541.0429.4021.2619.0118.451.200.930.93
Earnings Per Share-1.34-1.18-1.13-1.50-0.67-0.60-8.870.33-6.58
Operating Cash Flow-51.98-43.33-29.77-29.73-8.24-4.28-15.54-10.4713.85
Capital Expenditures-0.14-0.13-0.29-0.70-0.27-0.21-0.08-0.32-0.18
Free Cash Flow-52.13-43.46-30.06-30.44-8.51-4.49-15.62-10.7913.67
Cash & Equivalents15821012440.0946.8055.202.3117.3728.17
Total Debt3.62--------
Net Cash / Debt15521012440.0946.8055.202.3117.3728.17
Assets16821512942.3948.4657.265.2818.4228.91
Liabilities13.779.378.887.097.996.462.385.8920.45
Book Value15420512035.3040.4750.802.9112.538.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GlycoMimetics, Inc.
Country United States
Employees 57
CEO Rachel K. King

Stock Information

Ticker Symbol GLYC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GLYC
IPO Date January 10, 2014

Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.